TY - JOUR T1 - Statistical framework for studying the spatial architecture of the tumor immune microenvironment JF - medRxiv DO - 10.1101/2021.04.27.21256104 SP - 2021.04.27.21256104 AU - Christopher Wilson AU - Ram Thapa AU - Jordan Creed AU - Jonathan Nguyen AU - Carlos Moran Segura AU - Travis Gerke AU - Joellen Schildkraut AU - Lauren Peres AU - Brooke L. Fridley Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/29/2021.04.27.21256104.abstract N2 - New technologies, such as multiplex immunofluorescence microscopy (mIF), are being developed and used for the assessment and visualization of the tumor immune microenvironment (TIME). These assays produce not only an estimate of the abundance of immune cells in the TIME, but also their spatial locations; however, there are currently few approaches to analyze the spatial context of the TIME. Thus, we have developed a framework for the spatial analysis of the TIME using Ripley’s K, coupled with a permutation-based framework to estimate and measure the departure from complete spatial randomness (CSR) as a measure of the interactions between immune cells. This approach was then applied to ovarian cancer using mIF collected on intra-tumoral regions of interest (ROIs) and tissue microarrays (TMAs) from 158 high-grade serous ovarian carcinoma patients in the African American Cancer Epidemiology Study (AACES) (94 subjects on TMAs resulting in 259 tissue cores; 91 subjects with 254 ROIs). Cox proportional hazard models were constructed to determine the association of abundance and spatial clustering of tumor-infiltrating lymphocytes, cytotoxic T-cells, and regulatory T-cells, and overall survival. We found that EOC patients with high abundance and low spatial clustering of tumor-infiltrating lymphocytes and cytotoxic T-cells in their tumors had the best overall survival. In contrast, patients with low levels of regulatory T-cells but with a high level of spatial clustering (compare to those with a low level of spatial clustering) had better survival. These findings underscore the prognostic importance of evaluating not only immune cell abundance but also the spatial contexture of the immune cells in the TIME. In conclusion, the application of this spatial analysis framework to the study of the TIME could lead to the identification of immune content and spatial architecture that could aid in the determination of patients that are likely to respond to immunotherapies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is supported by K99/R00CA218681 (PI: Peres). The AACES is supported by R01CA237318 (PI: Schildkraut, Lawson) and R01CA142081 (PI: Schildkraut).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol, consent forms and questionnaire were approved by the Institutional Review Boards (IRB) at Duke University Medical Center, Baylor College of Medicine, Case Western Reserve University School of Medicine, Louisiana State University, Robert Wood Johnson Medical School/Rutgers Cancer Institute, Wayne State University, the University of Alabama-Birmingham, the Medical University of South Carolina and the University of Tennessee-Knoxville. Additionally, the protocol was approved by central cancer registries in the states of Alabama, Georgia, North Carolina, South Carolina, Tennessee and Texas, SEER (Surveillance, Epidemiology and End Results) registries in New Jersey, Louisiana, and the Detroit metropolitan area, and 9 individual hospital systems in Ohio. According to the protocol required at each site, either written consent is obtained or consent to contact the women is assumed if the physician does not object within a reasonable period of time (2 to 3 weeks) after notification.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to the AACES mIF data used in testing and illustrating the method will be made available upon reasonable request to the AACES investigators, please contact Dr. Lauren Peres. ER -